MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Cash Conversion Cycle 2011-2026 | VIVO
Annual Cash Conversion Cycle Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 201 | 232 | 206 | 208 | 212 | 215 | 250 | 195 | 201 | 208 | 199 | 221 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 250 | 195 | 212 |
Quarterly Cash Conversion Cycle Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 266 | - | - | 163 | 194 | - | 283 | 245 | 186 | 118 | 198 | 159 | 225 | 113 | 213 | 220 | 220 | 108 | 222 | 215 | 209 | 107 | 215 | 45 | 50.1 | 52.6 | 48.8 | 53.3 | 52.1 | 50.9 | 49.7 | 48.2 | 44.5 | 45.4 | 44.9 | 43.5 | 49.6 | 48.8 | 50.7 | 50.9 | 48.3 | 50.8 | 52.6 | 48.5 | 55.6 | 54.8 | 56.6 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 283 | 43.5 | 115 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
224 | $ 9.25 | -0.11 % | $ 616 M |  USA |
|
Biodesix
BDSX
|
41.7 | $ 14.56 | -0.27 % | $ 1.89 B | USA |
 |
DarioHealth Corp.
DRIO
|
115 | $ 8.45 | - | $ 33.7 M |  Israel |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
IDEXX Laboratories
IDXX
|
103 | $ 566.57 | -1.17 % | $ 45.6 B | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 462.67 | -0.84 % | $ 13.3 B | USA |
 |
Illumina
ILMN
|
142 | $ 121.35 | -2.45 % | $ 19.3 B | USA |
 |
Trinity Biotech plc
TRIB
|
136 | $ 0.62 | 1.06 % | $ 61.9 M |  Irlanda |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
OPKO Health
OPK
|
242 | $ 1.14 | -2.44 % | $ 791 M | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
29.4 | $ 16.93 | -2.48 % | $ 379 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
VolitionRx Limited
VNRX
|
52.3 | $ 0.19 | -3.63 % | $ 18.3 M |  Singapore |
 |
Charles River Laboratories International
CRL
|
65 | $ 160.77 | -2.64 % | $ 7.97 B | USA |
 |
Organovo Holdings
ONVO
|
-82.8 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Waters Corporation
WAT
|
731 | $ 295.27 | -1.76 % | $ 17.6 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-1.24 K | $ 4.79 | 6.32 % | $ 2.57 M | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
Exagen
XGN
|
-3.23 | $ 2.71 | -2.87 % | $ 58.4 M | USA |
 |
Interpace Biosciences
IDXG
|
44.9 | $ 1.73 | 2.37 % | $ 7.59 M | USA |
 |
Soleno Therapeutics
SLNO
|
-398 | $ 31.12 | -2.23 % | $ 1.58 B | USA |
 |
RadNet
RDNT
|
34.5 | $ 57.9 | -2.54 % | $ 4.35 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Thermo Fisher Scientific
TMO
|
70 | $ 482.91 | -1.22 % | $ 182 B | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Senseonics Holdings
SENS
|
36.1 | $ 6.53 | -0.53 % | $ 272 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 265.93 | -0.91 % | $ 22.1 B | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 7.58 | -2.32 % | $ 971 M | USA |
 |
Psychemedics Corporation
PMD
|
45.3 | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-3.19 | $ 26.54 | -2.43 % | $ 34.4 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.22 | -1.43 % | $ 918 M | USA |